Samsung’s Latest Health Play Takes Aim at the Ozempic Gold Rush
The six-month study will compare 100 adults using Galaxy Watch8 tracking and exercise guidance with standard care and DXA scans.
- On Thursday, Samsung Electronics announced a joint study with Massachusetts General Hospital and Harvard Medical School researchers to investigate whether the Galaxy Watch8 helps GLP-1 patients preserve muscle mass during weight-loss treatment.
- Researchers note that while GLP-1 medications effectively treat weight, patients may experience significant muscle reduction, with studies suggesting muscle can account for 40% to 50% of weight lost during treatment.
- Dr. Melissa Putman, director of the MGH Diabetes Research Center, will lead the study of 100 adults, dividing participants into two groups: one using Galaxy Watch8 for body composition monitoring and another receiving standard care.
- Putman stated the center aims to provide "clinicians a more holistic view of treatment impact," allowing for data-driven adjustments to care plans through continuous wearable monitoring of activity and heart rate.
- Samsung regularly collaborates with educational institutions to enhance health monitoring, having previously worked with Stanford University on sleep apnea detection and Chung-Ang University Gwangmyeong Hospital to predict fainting with "high accuracy.
13 Articles
13 Articles
Samsung is teaming up with Mass General Hospital to study smartwatch monitoring for weight-loss drug patients
The six-month clinical study will enroll 100 adults starting weight-loss drug therapy to test whether smartwatch data can help manage muscle loss
Samsung’s latest health play takes aim at the Ozempic gold rush
Samsung and Mass General are studying whether Galaxy Watch8 can support adults starting GLP-1RA therapy by tracking activity, heart rate, body composition, and muscle changes during treatment.
Samsung Electronics Partners with Harvard MGH for Study Tracking Muscle Loss in GLP-1 Patients Samsung Electronics is expanding its digital health research utilizing the Galaxy Watch in partnership with Massachusetts General Hospital, affiliated with Harvard Medical School. By tracking changes in body composition and activity levels of patients taking GLP-1 class treatments using wearable devices...
Coverage Details
Bias Distribution
- 50% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium











